Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. (Q34528550)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q56629673)
(Q37374768)
(P304) 4292-4302
(P407) (Q1860)
(P433) 21
(P478) 20
(P577) Friday, November 1, 2002
(P921) (Q5452194)
(Q181600)
(Q323936)
(Q725307)
(P1433) (Q400292)
(P1476) "Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types" (language: en)
(P2093) D Rischin
M Ranson
H Calvert
E Raymond
D G Kieback
S B Kaye
T Bjork
S D Averbuch
A Feyereislova
H Swaisland
F Rojo
J Albanell
J Baselga
other details
description scientific article

External Links